Ceccarelli C, Pacini F, Lippi F, Elisei R, Arganini M, Miccoli P, Pinchera A
Cattedra di Endocrinologia, University of Pisa, Italy.
Surgery. 1988 Dec;104(6):1143-8.
We report on 49 patients younger than 18 years at diagnosis, of 776 patients with thyroid cancer, seen in our institution in the last 17 years. Female/male ratio was 2.2:1. Histologic type was papillary in 44, follicular in 4, and medullary in 1. Initial treatment was near-total thyroidectomy with or without neck dissection. Surgical complications (vocal cord palsy, permanent hypoparathyroidism, or both) were found in 25 patients and were usually associated with more advanced primary tumors. At surgery, node metastases were present in 73% of the patients and lung metastases, detected by chest x ray films, in 6%. Patients were treated with thyroid suppressive therapy and, except the one with medullary cancer, with radioiodine (131I) therapy. After a mean follow-up of 7.7 +/- 4.4 years (range, 1 to 17 years), one patient with lung metastases died of respiratory failure. Of 36 patients who have been followed up more than 4 years, 22 (61.1%) are now cured, and 14 have metastases (to lymph nodes, 2; to nodes and lung, 10; and to lung, 2). Since 1977 serum thyroglobulin (Tg) was used routinely as a tumor marker for differentiated thyroid cancer. After operation, Tg was elevated in all patients both not receiving (mean +/- SE, 902 +/- 380 ng/ml) and receiving (44 +/- 15 ng/ml) suppressive therapy; after 131I treatment, serum Tg dropped to 104 +/- 50 and 7.3 +/- 1.7 ng/ml, without and with suppressive therapy, respectively. Of 11 patients with lung metastases treated with 131I, respiratory function, as assessed by means of spirometry, was normal in three, mildly reduced in six, and severely impaired in two (including the one who died). In conclusion, our study indicates that thyroid cancer in young patients is rather advanced at initial examination and usually associated with node and, less frequently, lung metastases. Total thyroidectomy, radioiodine treatment, and thyroid suppressive therapy represent an effective combination of treatments for this disease and allow a good quality of life. The most serious adverse effect is represented by the high incidence of surgical complications and by pulmonary restrictive disease in relation to lung metastases.
我们报告了在过去17年里在我们机构就诊的776例甲状腺癌患者中,49例诊断时年龄小于18岁。男女比例为2.2:1。组织学类型为乳头状癌44例,滤泡状癌4例,髓样癌1例。初始治疗为近全甲状腺切除术,伴或不伴颈部清扫术。25例患者出现手术并发症(声带麻痹、永久性甲状旁腺功能减退或两者皆有),且通常与更晚期的原发性肿瘤相关。手术时,73%的患者存在淋巴结转移,胸部X线片检测到6%的患者有肺转移。患者接受甲状腺抑制治疗,除髓样癌患者外,均接受放射性碘(131I)治疗。平均随访7.7±4.4年(范围1至17年),1例肺转移患者死于呼吸衰竭。在36例随访超过4年的患者中,22例(61.1%)现已治愈,14例有转移(淋巴结转移2例;淋巴结和肺转移10例;肺转移2例)。自1977年以来,血清甲状腺球蛋白(Tg)被常规用作分化型甲状腺癌的肿瘤标志物。术后,未接受抑制治疗(平均±标准差,902±380 ng/ml)和接受抑制治疗(44±15 ng/ml)的所有患者Tg均升高;131I治疗后,血清Tg分别降至104±50和7.3±1.7 ng/ml,分别为未接受和接受抑制治疗的情况。在11例接受131I治疗的肺转移患者中,通过肺活量测定评估,3例呼吸功能正常,6例轻度降低,2例严重受损(包括死亡的1例)。总之,我们的研究表明,年轻患者的甲状腺癌在初次检查时病情相当严重,通常伴有淋巴结转移,较少伴有肺转移。全甲状腺切除术、放射性碘治疗和甲状腺抑制治疗是该疾病的有效治疗组合,可使生活质量良好。最严重的不良反应表现为手术并发症的高发生率以及与肺转移相关的肺部限制性疾病。